cutaneous squamous cell carcinoma
Oncology · 2020–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pembrolizumab Treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) that is not curable by surgery or radiation. | Nov 2023 | Recommended with restriction | input received Skin Cancer Advocacy Network · Medical Oncology Group |
| cemiplimab Treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or… | Mar 2022 | Recommended with restriction | 33 individuals Australian Skin Cancer Foundation · Rare Cancers Australia · Skin Cancer Advocacy Network · Melanoma Patients Australia · Medical Oncology Group |
| cemiplimab Treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery… | Nov 2020 | Not recommended | input received Medical Oncology Group · Eastern Cooperative Oncology Group |
Who spoke
Medical Oncology Group · Skin Cancer Advocacy Network · Australian Skin Cancer Foundation · Rare Cancers Australia · Melanoma Patients Australia · Eastern Cooperative Oncology Group
What the PBS pays
$877M in government benefit over 2024–25, across 105,626 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pembrolizumab | $739.6M |
| cemiplimab | $137.9M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| cemiplimabCemiplimab for treating advanced cutaneous squamous cell carcinoma | TA802 | recommended restricted | 2022-06 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.